Pulmonary infection is one of the life-threatening complications occurring during allogeneic hematopoietic stem cell transplantation (alloHSCT), even when prophylactic measures have been employed. Few studies have investigated whether pulmonary infection affects platelet recovery during alloHSCT.
Pulmonary Infection Within 100 Days After Transplantation Impaired Platelet Recovery in Patients with Hematologic Malignancies:
A Propensity-Score-Matched Analysis BCEF 1 Roujia Wang* BCEF 1 Aijie Huang* CD 2 Qi Chen CD 1 Libing Wang C 1 Lei Gao C 1 Huiying Qiu C 1 Xiong Ni C 1 Weiping Zhang C 1 Jianmin Yang AEG 1 Jianmin Wang AEG 1 Xiaoxia Hu Background Impaired platelet recovery occurs in 5-37% of patients who received allogeneic hematopoietic stem cell transplantation (al-loHSCT) [1, 2] . Several possible mechanisms may contribute to impaired platelet recovery, including impaired thrombopoiesis and increased platelet consumption [3] . Complications of al-loHSCT, such as graft versus host disease (GvHD), hepatic venous sinus obstruction syndrome, thrombotic microangiopathy, and infections (bacterial, virus, and fungal), and their corresponding therapies are associated with impaired platelet recovery, even in the presence of full recovery of neutrophils [4] [5] [6] [7] [8] [9] [10] .
Alterations in platelet counts during acute lung injury have been studies by several groups. Schneider and colleagues studied the fate of platelets in 15 patients with severe acute respiratory failure; among them, 10 patients developed thrombocytopenia (<100 000 platelets/microliters) [11] . In another study, Carvalho et al. studied platelet function in 13 acute respiratory failure patients admitted for intensive care, 6 acutely ill intensive care patients without evidence of acute lung injury, and 10 normal subjects [12, 13] , showing that patients with acute respiratory failure had quantitative and qualitative platelet defects that may contribute to thrombotic and hemorrhagic complications compared with those without acute respiratory failure.
Pulmonary infection occurs in 40-60% of alloHSCT recipients, and has been reported to be an important predictor of survival [14] [15] [16] . Previous studies have reported that the incidence rate of early-stage infections ranges from 15% [17] to 64.3% [14] , and pulmonary infection is a common problem [15] . The reasons why pulmonary infection is associated with decreased survival of alloHSCT recipients mostly involve treatment-related complications [18] , but few studies have focused on platelet recovery in patients with pulmonary complications during the alloHSCT procedure. The aim of the present study was to evaluate the effect of pulmonary infection on platelet recovery within the first 100 days after alloHSCT.
Material and Methods

Patients
From January 2011 to December 2018, 319 patients received alloHSCT at the Institute of Hematology, Changhai Hospital; 66 patients relapsed (21%), and 253 patients without relapse were included in the present study. Among these 253 patients, 62 patients (25%) developed pulmonary infection within 100 days. For each pulmonary infection case, a set of 2 patients was chosen as control from the remaining patients who were without pulmonary infection after matching for age (<20 y, 20-40 y, 41-60 y, or >60 y), disease and stage, time from diagnosis to transplantation, median CD34 + cells, and mononucleated cells transplanted. Fifty patients with pulmonary infection who had 2 matched controls were enrolled in a propensity score-matched study, and the remaining 12 patients who did not have matched controls were not included in propensity analysis. All procedures complied with the Helsinki Declaration standards and were approved by the Institutional Review Board of Changhai Hospital, Shanghai, China. The requirement for written informed consent was waived because the study used retrospective data from medical records, and there were no interventions performed in patients.
Transplant procedure
The transplant procedure was described previously [19] Forty patients (40/50, 80%) received a busulfan and cyclophosphamide (BuCy)-based conditioning regimen that consisted of cytarabine (4 g/m 2 /d) intravenously on days -10 to -9; and Bu (3.2 mg/kg/d) intravenously on days -8 to -6; CTX (1.8 g/m 2 /d), intravenously on days -5 to -4; Me-CCNU (250 mg/m 2 /d), orally once on day -3, and intravenously on days -5 to -2. Ten patients (10/50, 20%) were treated with an FBA conditioning regimen that included fludarabine, 30 mg/m 2 /day on days -10 to -6; Bu, 0.8 mg/kg every 6 h on days -5 to -3; and cytosine arabinoside, 1.5 g/m 2 /day on days -10 to -6). Antithymoglobulin (ATG) was used in patients who underwent al-loHSCT from a human leukocyte antigen (HLA)-mismatched donor. The acute graft versus host disease (aGvHD) prophylaxis regimen was as previously reported [20] .
Infection prophylaxis and monitoring
Pulmonary high-resolution computed tomography (HRCT) was performed before alloHSCT. Patients were assigned to the horizontal laminar flow unit before conditioning. Sulfamethoxazole/ trimethoprim was used to prevent prophylaxis Pneumocystis jiroveci. The preemptive treatment for CMV reactivation consisted of ganciclovir or valganciclovir. All patients received oral levofloxacin and fluconazole, unless they were receiving other medications for a previous infection. For secondary prevention, patients with history of invasive fungal disease (IFD) before alloHSCT received intravenous voriconazole or corresponding effective antifungal drugs. Within the first 3 months after alloHSCT, sulfamethoxazole/trimethoprim, fluconazole, and ganciclovir were administrated alternatively. CMV DNA, Epstein-Barr virus (EBV), procalcitonin (PCT), C-reactive protein (CRP), 1, 3-b-D-glucan assay (G assay), and galactomannan test (GM assay) were measured once a week until 3 months after alloHSCT.
Diagnosis of pulmonary infections and treatment
Samples were collected from the sputum, blood, and bronchoalveolar lavage (BAL) fluid if possible. Chest HRCT was performed when patients were highly suspected to have a pulmonary infection. PCT and CRP, as well as G and GM assays, were measured. Cultivation or next-generation sequencing of BAL fluid or lung biopsy were performed to confirm pathogenic organisms.
Once pneumonia was diagnosed, empirical broad-spectrum antibiotics were instituted if there was suspected bacterial pneumonia until a specific pathogen was identified, and targeted therapy was initiated accordingly. Active IFD was defined as possible, probable, or proven according to the EORTC criteria [21] . The specific antifungal treatment was administrated at the discretion of the managing physician. In addition, we used PSI (Pneumonia Severity Index) scores to weigh the prognosis of pulmonary infection [22] .
Definitions of clinical outcome
Platelet count ³20×10 9 /L for 7 consecutive days without transfusion was defined as platelet engraftment (primary platelet recovery). Secondary failure of platelet recovery (SFPR) was diagnosed in patients who had previously fulfilled the criteria for trilineage recovery after alloHSCT, with platelet count <20×10 9 /L or ³20×10 9 /L with transfusion for more than 7 consecutive days [23, 24] . Good graft function (GGF) was defined as persistent successful engraftment (ANC > 0.5×10 9 /L for 3 consecutive days, PLT counts >20×10 9 /L for 7 consecutive days and hemoglobin levels > 70 g/L without transfusion support) beyond 28 days after HSCT [25] . Prolonged thrombocytopenia (PT) was defined as the engraftment of all peripheral blood cell lines other than a platelet count £80×10 9 /L for more than 90 days after alloHSCT [9, 23] . Impaired platelet recovery was included in PT and SFPR. CMV and EBV viremia were defined as >1000 viral copies/ml plasma by PCR. Diffuse pulmonary infection was defined as diffuse lesions in ³2 pulmonary lobes. Scattered pulmonary infection was defined as lung consolidation of 1 lung segmental lobe, or single and multiple lung nodules based on CT scan. Chimerism analyses were performed by DNA fingerprinting for single-nucleotide polymorphism in bone marrow samples as introduced in our previous publication [26] (sensitivity >0.01% recipient signals).
Statistical analysis
Greedy-type 1: 2 matching technology without replacement was performed to match patients with pulmonary infection and patients without (Figure 1 ). Matching of the logit of the propensity-score began with high accuracy (0.00001), and then gradually decreased to minimum precision accuracy (0.1). Univariate and multivariate logistic regression were used to examine the risk factors associated with platelet recovery. Table 3 ). These 4 factors were then enrolled in the multivariable analysis. Multivariable logistic regression showed that pulmonary infection was a significant independent risk factor for impaired platelet recovery (OR: 5.335, 95% CI: 2.735-10.407, P<0.001, Table 4 ). 
Survival outcomes
The probability of OS at 3 years after alloHSCT was 71.5±6.4% for patients with pulmonary infection and 80.2±4.2% for patients without pulmonary infection (P=0.132). The patients were further grouped into 2 subgroups depending on infection severity. Grade III-IV infection conferred a worse OS at 3 years (54.2±10.2% vs. 88.1±6.4%, P=0.014) compared to patients with grade I-II infection (Figure 2 ). The probability of OS in patients with pulmonary infection in the first month (n=18) was 66.7±11.1%, and 76.9±8.3% for patients (n=26) who developed pulmonary infection during the second and third months. (P=0.410).
The probability of OS at 3 years after alloHSCT was 55.2±7.3% in the group with impaired platelet recovery and 87.9±3.6% in patients with GGF (P<0.001). Patients with PT or SFPR had inferior survival compared with patients with GGF (3-year OS: PT: 69.9±8.4%, P=0.005, Figure 3A ; SFPR: 29.4±11.1%, P<0.001, Figure 3B ). TRM was increased in patients with impaired platelet recovery (impaired platelet recovery: 44.78±0.55% vs. GGF: 12.12±0.13%, P<0.001). The probabilities of TRM at 3 years were 30.13±0.74% in patients with PT and 70.59±1.39% in patients with SFPR ( Figure 3C, 3D ).
Discussion
To the best of our knowledge, this study is the first on platelet recovery and pulmonary infection within 100 days after al-loHSCT. We performed propensity score matching to balance baseline patient characteristics. The incidence of PT in patients with pulmonary infection were 44% (22/50) and 9% (9/100) in the corresponding matched group (P<0.001). 
